Ali Behbahani has bought stock on 13 days since Sep 2018
Director at CRISPR Therapeutics AG, and 11 other companies
SEC CIK 0001613867 · Filings on SEC.gov ↗
Ali Behbahani's record
3 months after each buy, from the first price a copier could get.
5 buys since 2018 with 3 months of prices.
Companies
- CRSP CRISPR Therapeutics AGDirector
- SGP SpyGlass Pharma, Inc.Director and 10% owner
- MBX MBX Biosciences, Inc.10% owner
- SVRA Savara Inc.10% owner
- BDTX Black Diamond Therapeutics, Inc.Director
- GNCA Genocea Biosciences, Inc.Director and 10% owner
- TRVI Trevi Therapeutics, Inc.10% owner
- MTCR Metacrine, Inc.10% owner
- MRKR Marker Therapeutics, Inc.10% owner
- RGLS Regulus Therapeutics Inc.10% owner
- AKUS Akouos, Inc.10% owner
- ADAP Adaptimmune Therapeutics PlcDirector
Every filing
16 filings since Sep 2018, newest first
CRISPR Therapeutics AG
Director
Spyglass Pharma, Inc.
Director and 10% owner
Mbx Biosciences, Inc.
10% owner
Savara Inc
10% owner
Black Diamond Therapeutics, Inc.
Director
Genocea Biosciences, Inc.
Director and 10% owner
Trevi Therapeutics, Inc.
10% owner
Metacrine, Inc.
10% owner
Marker Therapeutics, Inc.
10% owner
Regulus Therapeutics Inc.
10% owner
Akouos, Inc.
10% owner
Black Diamond Therapeutics, Inc.
Director
Adaptimmune Therapeutics Plc
Director
Trevi Therapeutics, Inc.
10% owner
Regulus Therapeutics Inc.
10% owner
Adaptimmune Therapeutics Plc
Director
About Ali Behbahani
Ali Behbahani, M.D., M.B.A. is a Partner and Co-Head of the Healthcare team at New Enterprise Associates (NEA), a venture capital firm, where he has worked since 2007, specializing in biopharmaceuticals, medical devices, and related sectors.( He serves as an Independent Director and 10% Owner of SpyGlass Pharma, Inc. (SGP), with recent insider transactions including the conversion of NEA funds' preferred stock to common stock and the acquisition of 937,500 shares for $15 million around the company's IPO in February 2026.(
Behbahani holds an MD from the University of Pennsylvania School of Medicine, an MBA from The Wharton School, and bachelor’s degrees in biomedical engineering, electrical engineering, and chemistry from Duke University.( His career highlights include prior roles at The Medicines Company, Morgan Stanley, and Lehman Brothers, research at the National Institutes of Health and Duke, and board seats at numerous biotech firms such as CRISPR Therapeutics (since 2015), Nkarta (Chairman since 2019), Arcellx, Black Diamond Therapeutics, Monte Rosa Therapeutics, and Korro Bio.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.